Prospects for Aldeyra's dry eye disease candidate reproxalap were hit last month after the drug failed to hit its primary objective in a phase 3 trial, but the company isn't giving up and h
Novartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing it to make a loss of $200 million this quarter.